AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31448214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT) with a prescription dose of 68.1 Gy in 30 fractions
Number of subjects: 35
Study 31448496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (CysC)
Number of subjects: 173
Study 31448496 — intervention group
Group type: COMPARATOR
Intervention: Creatinine
Number of subjects: 173
Study 31449299 — intervention group
Group type: EXPERIMENTAL
Intervention: More aggressive organ acceptance practices
Number of subjects: 156089
Study 31449299 — intervention group
Group type: EXPERIMENTAL
Intervention: Redesigned system with more aggressive organ acceptance practices
Number of subjects: 156089
Study 31449299 — intervention group
Group type: COMPARATOR
Intervention: Kidney transplant in the United States
Number of subjects: 156089
Study 31449299 — intervention group
Group type: COMPARATOR
Intervention: Kidney transplant in France
Number of subjects: 156089
Study 31449299 — intervention group
Group type: COMPARATOR
Intervention: Kidney quality over time in the United States
Number of subjects: 156089
Study 31449299 — intervention group
Group type: COMPARATOR
Intervention: Kidney quality over time in France
Number of subjects: 156089
Study 31449468 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen DD4A (vincristine, dactinomycin, and doxorubicin) for stage I/II disease
Number of subjects: 2511
Study 31449468 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen M (vincristine, dactinomycin, doxorubicin alternating with cyclophosphamide and etoposide) and radiation therapy for stage III/IV disease
Number of subjects: 2511
Study 31449468 — intervention group
Group type: COMPARATOR
Intervention: Historical NWTS-5 comparison group
Number of subjects: 2511
Study 31449522 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for Buruli ulcer
Number of subjects: 354
Study 31449522 — intervention group
Group type: EXPERIMENTAL
Intervention: High bacterial load in lesion samples
Number of subjects: 354
Study 31449522 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive M. ulcerans culture
Number of subjects: 354
Study 31449522 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive microscopy results
Number of subjects: 354
Study 31449522 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of plaques, oedematous lesions, and category II lesions
Number of subjects: 354
Study 31449522 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to complete healing
Number of subjects: 354
Study 31449806 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior repair
Number of subjects: 374
Study 31449806 — intervention group
Group type: COMPARATOR
Intervention: No posterior repair
Number of subjects: 374
Study 31449806 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success regardless of posterior repair
Number of subjects: 374
Study 31450823 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory therapy (CANTOS Trial, NCT01327846)
Number of subjects: 0
Study 31451367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with first-line chemotherapy (capecitabine/oxaliplatin)
Number of subjects: 714
Study 31451367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with first-line chemotherapy
Number of subjects: 714
Study 31451367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab after disease progression
Number of subjects: 714
Study 31451367 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab with capecitabine-based chemotherapy vs fluorouracil-based regimens
Number of subjects: 714
Study 31451409 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma GFAP concentrations measured in patients with CT-negative and MRI-positive findings
Number of subjects: 450
Study 31451409 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma GFAP concentrations in patients with CT-negative and MRI-negative findings
Number of subjects: 450
Study 31451409 — intervention group
Group type: COMPARATOR
Intervention: Plasma GFAP concentrations in orthopaedic trauma controls
Number of subjects: 450
Study 31451409 — intervention group
Group type: COMPARATOR
Intervention: Plasma GFAP concentrations in healthy controls
Number of subjects: 450
Study 31451445 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab, 60 µg/m²
Number of subjects: 0
Study 31451681 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus
Number of subjects: 398
Study 31451936 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Back Pain (MBP)
Number of subjects: 258
Study 31451936 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Leg Pain (MLP)
Number of subjects: 258
Study 31452001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation using cryoablation (PVI-C)
Number of subjects: 2125
Study 31452586 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (blood glucose level ≥ 169 mg/dL)
Number of subjects: 856
Study 31452586 — intervention group
Group type: COMPARATOR
Intervention: Lower blood glucose level (<169 mg/dL)
Number of subjects: 856
Study 31452899 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO)
Number of subjects: 70
Study 31452899 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCO
Number of subjects: 70
Study 31452902 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily tacrolimus dosing
Number of subjects: 38
Study 31452902 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily tacrolimus dosing
Number of subjects: 38
Study 31452953 — intervention group
Group type: EXPERIMENTAL
Intervention: Allium sativum extract as an intracanal irrigant
Number of subjects: 90
Study 31452953 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 31453076 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including scripted counseling via text messages and brief motivational interviewing delivered by telephone
Number of subjects: 69
Study 31453076 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a handout on the benefits of physical activity
Number of subjects: 69
Study 31453424 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy product intake (HD) (≥4 servings/d) for 6 weeks
Number of subjects: 27
Study 31453424 — intervention group
Group type: COMPARATOR
Intervention: Adequate dairy product intake (AD) (≤2 servings/d) for 6 weeks
Number of subjects: 27
Study 31453428 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly mailed healthy lifestyle intervention toolkit
Number of subjects: 450
Study 31453766 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated left ventricular mass quantified by MRI
Number of subjects: 0
Study 31453766 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) score
Number of subjects: 0
Study 31454374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebola virus fluorescence reduction neutralization assay (FRNA)
Number of subjects: 0
Study 31454374 — intervention group
Group type: COMPARATOR
Intervention: Filovirus Animal Non-clinical Group (FANG) ELISA
Number of subjects: 0
Study 31454510 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated fetal weight percentage difference
Number of subjects: 140
Study 31454510 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight discordance ≥18%
Number of subjects: 140
Study 31454510 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated fetal weight percent difference
Number of subjects: 140
Study 31454510 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of dichorionic pregnancies exceeding a fixed discordance cut point
Number of subjects: 140
Study 31455225 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Tai-Chi (iTC) training for 8 weeks
Number of subjects: 50
Study 31455225 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Tai-Chi (tTC) training for 8 weeks
Number of subjects: 50
Study 31455225 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 50
Study 31455358 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device for gait rehabilitation (30 min walking sessions, 3 times per week for 4 weeks)
Number of subjects: 6
Study 31455612 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (all predictors included)
Number of subjects: 438
Study 31455612 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (QFT excluded)
Number of subjects: 438
Study 31455612 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 3 (ultrasonography excluded)
Number of subjects: 438
Study 31455612 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 4 (QFT and ultrasonography excluded)
Number of subjects: 438
Study 31455681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (0.3 or 1.0 mg/kg) and Nivolumab (3.0 mg/kg)
Number of subjects: 96
Study 31455681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab and Nivolumab
Number of subjects: 96
Study 31455684 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasound assessment before starting NIV (T0), after the first hour (T1), and after the second hour (T2).
Number of subjects: 22
Study 31455684 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasound assessment at T0, T1, and T2.
Number of subjects: 22
Study 31455696 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of TRACK
Number of subjects: 321
Study 31455712 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation with 1200 mg of elemental calcium during pregnancy and lactation
Number of subjects: 1643
Study 31455712 — intervention group
Group type: EXPERIMENTAL
Intervention: Early life exposure to lead
Number of subjects: 1643
Study 31455712 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary factors, genetic polymorphisms, timing of exposure
Number of subjects: 1643
Study 31455712 — intervention group
Group type: EXPERIMENTAL
Intervention: Other toxicants (phthalates, bisphenol A, mercury, manganese, cadmium, organophosphates, fluoride)
Number of subjects: 1643
Study 31455743 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiecho fMRI denoising
Number of subjects: 0
Study 31455743 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31455851 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus fludarabine and cyclophosphamide (G-FC)
Number of subjects: 140
Study 31456070 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) using the Neuropathic Pain Scale (NPS) and Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity (FACT/GOG-Ntx)
Number of subjects: 49
Study 31456070 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing (QST) measuring tactile and vibration detection thresholds
Number of subjects: 49
Study 31456142 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201 (administered orally once every week)
Number of subjects: 18
Study 31456261 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor 0.32 mg/kg and bortezomib 1.3 mg/m²
Number of subjects: 58
Study 31456261 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor in combination with bortezomib
Number of subjects: 58
Study 31456363 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning (DL) algorithm
Number of subjects: 412030
Study 31456363 — intervention group
Group type: COMPARATOR
Intervention: Cox hazard regression
Number of subjects: 412030
Study 31456431 — intervention group
Group type: EXPERIMENTAL
Intervention: ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules
Number of subjects: 0
Study 31456431 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31456995 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training combined with stretching
Number of subjects: 0
Study 31456995 — intervention group
Group type: COMPARATOR
Intervention: Stretching alone
Number of subjects: 0
Study 31461380 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant single-agent oral talazoparib once per day for 6 months
Number of subjects: 20
Study 31462235 — intervention group
Group type: EXPERIMENTAL
Intervention: SGRQ-I
Number of subjects: 150
Study 31462235 — intervention group
Group type: COMPARATOR
Intervention: SGRQ
Number of subjects: 150
Study 31462235 — intervention group
Group type: COMPARATOR
Intervention: King's Brief Interstitial Lung Disease questionnaire (K-BILD)
Number of subjects: 150
Study 31462235 — intervention group
Group type: COMPARATOR
Intervention: University of California, San Diego Shortness of Breath Questionnaire (SOBQ)
Number of subjects: 150
Study 31462235 — intervention group
Group type: COMPARATOR
Intervention: Short Form-36 (SF-36)
Number of subjects: 150
Study 31462235 — intervention group
Group type: COMPARATOR
Intervention: Global Rating of Change Scales (GRCS)
Number of subjects: 150
Study 31462235 — intervention group
Group type: COMPARATOR
Intervention: 6-min walk test (6MWT)
Number of subjects: 150
Study 31462437 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of human enterovirus (HEV) in plasma
Number of subjects: 135
Study 31462437 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of human parechovirus (HPeV) in plasma
Number of subjects: 135
Study 31462437 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of adenovirus (AdV) in plasma
Number of subjects: 135
Study 31462437 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of human herpesvirus type 6 (HHV-6) in plasma
Number of subjects: 135
Study 31462437 — intervention group
Group type: EXPERIMENTAL
Intervention: Viraemia in children with FWS
Number of subjects: 135
Study 31462437 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic use in patients with viraemia
Number of subjects: 135
Study 31462437 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of serious bacterial infection (SBI) among patients with viraemia
Number of subjects: 135
Study 31462437 — intervention group
Group type: COMPARATOR
Intervention: Control cohort testing for viruses in blood
Number of subjects: 135
Study 31462933 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 38
Study 31462933 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 38
Study 31462933 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 38
Study 31463079 — intervention group
Group type: EXPERIMENTAL
Intervention: GAPcare intervention (multidisciplinary fall prevention protocol)
Number of subjects: 120
Study 31463079 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 120
Study 31463078 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-slow resistance training (HSR) combined with ultrasound-guided corticosteroid injection
Number of subjects: 20
Study 31463362 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher injection pressure (550 pound/inch)
Number of subjects: 100
Study 31463362 — intervention group
Group type: COMPARATOR
Intervention: Lower injection pressure
Number of subjects: 100
Study 31463362 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher injection pressure
Number of subjects: 100
Study 31463874 — intervention group
Group type: EXPERIMENTAL
Intervention: FACS-sorting of spermatozoa with fragmented DNA
Number of subjects: 104
Study 31463874 — intervention group
Group type: COMPARATOR
Intervention: Swim-up
Number of subjects: 104
Study 31464190 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM) program for pregnant women at risk of PIH
Number of subjects: 108
Study 31464589 — intervention group
Group type: EXPERIMENTAL
Intervention: Connection to Health (CTH), an electronic self-management support system
Number of subjects: 446
Study 31464712 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative delirium (POD) diagnosed using the Confusion Assessment Method for the ICU on postoperative day 1 or day 3.
Number of subjects: 800
Study 31464712 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent risk factors for POD include age, nature of intracranial lesion, frontal approach craniotomy, duration of surgery, presence of an episode of low pulse oxygenation at ICU admission, presence of inadequate emergence and emergence delirium, postoperative pain and presence of immobilising events.
Number of subjects: 800
Study 31464712 — intervention group
Group type: EXPERIMENTAL
Intervention: POD association with adverse outcomes and high costs.
Number of subjects: 800
Study 31464752 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral chronic neck pain patients
Number of subjects: 49
Study 31464769 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaries
Number of subjects: 5165
Study 31464769 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programs
Number of subjects: 5165
Study 31464935 — intervention group
Group type: EXPERIMENTAL
Intervention: Barricaid annular closure device
Number of subjects: 75
Study 31464935 — intervention group
Group type: COMPARATOR
Intervention: Historical controls from a previous European randomized trial
Number of subjects: 75
Study 31465427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty liver index (FLI)
Number of subjects: 389
Study 31465427 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in FLI
Number of subjects: 389
Study 31465427 — intervention group
Group type: COMPARATOR
Intervention: Full model including diabetes risk score, FPG, HbA1C and FLI
Number of subjects: 389
Study 31465427 — intervention group
Group type: COMPARATOR
Intervention: HOMA-IR
Number of subjects: 389
Study 31466481 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal ablation
Number of subjects: 0
Study 31466616 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation (AC) after bioprosthetic AVR
Number of subjects: 4832
Study 31466616 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation (AC) after surgical AVR (SAVR)
Number of subjects: 4832
Study 31466616 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation (Control group) after bioprosthetic AVR
Number of subjects: 4832
Study 31467059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (PD-1 inhibitor)
Number of subjects: 0
Study 31467127 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic alterations
Number of subjects: 0
Study 31467520 — intervention group
Group type: COMPARATOR
Intervention: fALFF analysis in broadband frequency band (~0.01-0.08 Hz)
Number of subjects: 63
Study 31467520 — intervention group
Group type: COMPARATOR
Intervention: fALFF analysis in slow-5 frequency band (~0.01-0.027 Hz)
Number of subjects: 63
Study 31467520 — intervention group
Group type: COMPARATOR
Intervention: fALFF analysis in slow-4 frequency band (0.027-0.07 Hz)
Number of subjects: 63
Study 31467520 — intervention group
Group type: COMPARATOR
Intervention: Overall fALFF analysis across three frequency bands
Number of subjects: 63
Study 31467583 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted (CR) diet
Number of subjects: 0
Study 31467699 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg of protein hydrolysate from Coldwater Shrimp
Number of subjects: 0
Study 31467699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31468255 — intervention group
Group type: EXPERIMENTAL
Intervention: Preattached multichannel intraluminal impedance monitoring combined with pH-metry
Number of subjects: 0
Study 31468637 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line glucose-lowering therapy
Number of subjects: 15992
Study 31468637 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with poor glycaemic control (HbA1c >8.0%)
Number of subjects: 15992
Study 31469058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin/doxorubicin administered during standard laparoscopy
Number of subjects: 13
Study 31469058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Number of subjects: 13
Study 31470902 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (Gazyvaro) combined with low-dose radiotherapy (LDRT)
Number of subjects: 93
Study 31471185 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor treatment
Number of subjects: 200
Study 31471185 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline DTI metrics
Number of subjects: 200
Study 31471185 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect sizes
Number of subjects: 200
Study 31471185 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal changes in DTI metrics
Number of subjects: 200
Study 31471313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day
Number of subjects: 14
Study 31471313 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 120 mg/day
Number of subjects: 14
Study 31471313 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sunitinib and regorafenib
Number of subjects: 14
Study 31471312 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2816126 (EZH2 inhibitor) at doses ranging from 50 to 3,000 mg twice weekly, given 3-weeks-on/1-week-off in 28-day cycles
Number of subjects: 41
Study 31471324 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL-2) therapy
Number of subjects: 0
Study 31471376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-azacytidine (AZA) 300 mg daily on days 1 to 14 and romidepsin (ROMI) 14 mg/m2 on days 8, 15, and 22 on a 35-day cycle
Number of subjects: 31
Study 31471376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-azacytidine (AZA) 100 mg daily on days 1 to 14 to 300 mg daily on days 1 to 21 and romidepsin (ROMI) 10 mg/m2 on days 8 and 15 to 14 mg/m2 on days 8, 15, and 22
Number of subjects: 31
Study 31471376 — intervention group
Group type: COMPARATOR
Intervention: Non-T-cell lymphoma patients
Number of subjects: 31
Study 31471433 — intervention group
Group type: EXPERIMENTAL
Intervention: Early point-of-care focused echocardiography (EPOCE) performed during the automated external defibrillator's analysis period.
Number of subjects: 8
Study 31471433 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCE asystole
Number of subjects: 8
Study 31471433 — intervention group
Group type: EXPERIMENTAL
Intervention: EPOCE technique
Number of subjects: 8
Study 31471442 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 37614
Study 31471442 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 37614
Study 31471961 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOODLIGHT test battery (active tests and passive monitoring)
Number of subjects: 76